Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ

- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions

- Mirum plans to submit an sNDA in H1 2027 to expand the ATEBRIOZ indication to pediatric patients aged 6 to <12 years

- Safety and efficacy findings consistent with PROGRESS Cohort 1; no new safety signals